RxDoctor Payments DataLook up a doctor →

Craig Schuring, DO

Critical Care Medicine · Savannah, GANPI 1447698360

Payments from drug & device makers

$12,426in general payments, 2019–2025

Across 537 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$2K
  • AstraZeneca$2K
  • GSK$1K
  • Actelion Pharmaceuticals US, Inc.$919
  • Boehringer Ingelheim$651
  • Mallinckrodt Hospital Products Inc.$599
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$1,61213%
  • Food & beverage$10,64086%
  • Education$1731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,426 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$248,369
Medicare patients
948
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag20$534,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter379$304,533
Tyvaso DpiTreprostinil12$298,146
OpsumitMacitentan11$161,059
Dupixent PenDupilumab35$156,909
OfevNintedanib Esylate11$142,544
XolairOmalizumab25$87,158
Breztri AerosphereBudesonide/Glycopyr/Formoterol88$62,289
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr75$42,473
Ambrisentan13$37,050
Breo ElliptaFluticasone/Vilanterol42$31,389
Spiriva RespimatTiotropium Bromide45$29,899
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$18,554
EliquisApixaban32$18,202
SymbicortBudesonide/Formoterol Fumarate32$9,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$919$696,05731 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,143$382,165508 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$651$190,99686 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,882$71,678120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →